The air you breathe is essential to your long-term health, but for some people it’s difficult to get enough oxygen into your bloodstream. If you suffer from pulmonary fibrosis, you know that it’s a condition that limits the air that can get through your lungs and into your blood because the tissues around and between air sacs in the lungs thicken and scar over time. The shortness of breath and difficulty getting enough oxygen get worse over time, causing significant fatigue.
What you might not know is that the scarring you experience that leads to thickening of tissues over time could actually be caused by several different factors in your environment, such as airborne toxins, lung diseases, radiation, or medical treatments. It can be difficult for healthcare professionals to pinpoint the exact cause, which leads to a diagnosis of idiopathic pulmonary fibrosis (IPF).
Traditional Treatment for IPF
Traditional treatment plans are designed to help slow down the progression of the tissue thickening process and to help you live a more fulfilling life. These often include corticosteroids, either on their own or in combination with drugs that will suppress the immune system.
There are also non-medicine treatments that doctors may provide, such as oxygen therapy and pulmonary rehabilitation. While these things cannot stop the scarring in the lungs, they can help patients function in their daily lives better than they would without the treatment.
A less common treatment option involves lung transplants, but these are generally reserved for younger patients with an aggressive form of the disease who are not responding to other treatments.
New Approaches to Treating IPF
Another thing you may not know about IPF is that today there are more options for treating this condition, which was not the case several years ago. One promising new treatment for the condition is the medication pirfenidone. In research studies it has been shown to keep the disease from progressing and also improve survival rates. Canadian trials have helped existing patients reduce the annual decline they see in their lung capacity and function over time. In one such trial, called ASCEND, patients that received pirfenidone had a 48 percent lower death rate and did not experience the worsening lung function that patients did who were taking a placebo pill. Unfortunately pirfenidone remains extremely expensive in the U.S. (costing about $8,000 a month from a U.S. pharmacy), so it’s difficult for patients to afford. For that reason many patients are turning to online pharmacies like Life Relay Health Care to get this promising new drug.
To buy pirfenidone and find out more about treatments for pulmonary fibrosis, contact Life Relay Health Care Solutions today. Our online Canadian pharmacy services help patients get the best treatments and medications for IPF for an affordable price.